Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study

Basit Öğe Kaydı
dc.contributor.authorYekeduz, Emre
dc.contributor.authorOzbay, Mehmet Fatih
dc.contributor.authorCaglayan, Dilek
dc.contributor.authorYildirim, Atila
dc.contributor.authorErol, Cihan
dc.contributor.authorYildirim, Hasan Cagri
dc.contributor.authorTunc, Sezai
dc.date.accessioned2024-02-23T13:43:32Z
dc.date.available2024-02-23T13:43:32Z
dc.date.issued2022
dc.departmentNEÜen_US
dc.description.abstractAim To compare survival outcomes, response rates, and adverse events (AEs) in proton pump inhibitor (PPI) user and nonuser patients with metastatic colorectal cancer (mCRC) treated with regorafenib. Methods We included 272 patients with mCRC treated with regorafenib in this study. Patients were divided into two categories according to their status of PPI use. The primary endpoint was overall survival (OS). The secondary endpoints were time to treatment failure (TTF), response rates, and safety. To exclude immortal time bias in survival analyses, we compared PPI non-user patients and all patients. Results There were 141 and 131 patients in the PPI non-user and user groups. Baseline characteristics were similar in each group. Pantoprazole was the most used PPI. At the median 35.2 (95% confidence interval (CI): 32.6-37.9) months follow-up, the median OS was similar in PPI non-user and all patients (6.9 months (95% CI: 5.3-8.5) and 7.7 months (95% CI:6.6-8.8), p = 0.913). TTF was also similar in PPI non-user and all patients (3.3 months (95% CI: 2.7-3.9) and 3.5 months (95% CI: 3.0-4.0), p = 0.661). In multivariable analysis, no statistically significant difference was observed between PPI user and nonuser groups in OS and TTF (hazard ratio (HR), 0.99; 95% CI, 0.77-1.28; p = 0.963 for OS; HR, 0.93; 0.77-1.20, p = 0.598 for TTF). The objective response rates (ORR) were similar in the PPI non-user and user groups (19.8% and 16.8%, p = 0.455). The rates of any grade AEs were also similar in each group. Conclusion This study found no worse outcome in the combined use of PPI and regorafenib among patients with mCRC.en_US
dc.identifier.doi10.1007/s00228-022-03403-1
dc.identifier.endpage1979en_US
dc.identifier.issn0031-6970
dc.identifier.issn1432-1041
dc.identifier.issue12en_US
dc.identifier.pmid36266366en_US
dc.identifier.scopus2-s2.0-85140336938en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1973en_US
dc.identifier.urihttps://doi.org/10.1007/s00228-022-03403-1
dc.identifier.urihttps://hdl.handle.net/20.500.12452/10849
dc.identifier.volume78en_US
dc.identifier.wosWOS:000870609400001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer Heidelbergen_US
dc.relation.ispartofEuropean Journal Of Clinical Pharmacologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDrug-Drug Interactionsen_US
dc.subjectAcid Suppressionen_US
dc.subjectRegorafeniben_US
dc.titleClinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu